NCI-2022-06279

A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vsPembrolizumab Alone in Treatment-nave Subjects with Advanced or Metastatic PD-L1High (TPSgt50) Non-small-small Cell Lung Cancer Without Actionable Genomic Alterations(Tropion-Lung08)

This randomized study compares two treatments for advanced lung cancer that hasn't been treated before. One treatment combines two drugs, one called Dato-DXd and Pembrolizumab, a type of immunotherapy, while the other uses only Pembrolizumab. People in the study have a lot of a certain protein called PD-L1 in their cancer cells, and their cancer doesn't have any other specific genetic changes that can be targeted with existing drugs.

PD-L1: PD-L1 is a protein that regulates the immune system's response to cancer cells, and helps cancer cells hide from the body's immune system.

randomized: Patients are randomly assigned to one of two groups. It's like flipping a coin to decide who gets which treatment

immunotherapy: The immune system helps fight cancer by sending the body's defense (immune) system to kill the cancer cells. Immunotherapy drugs target cancer cells to prevent them from multiplying and growing.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05215340

Clinical Trial Site: Einstein

To see all available clinical trials click here.